Holen Sie sich die Stockscreener-App
2.76
1.43%
-0.04
Vorhandelsmarkt:
2.76
Regulus Therapeutics Inc Aktie (RGLS) Neueste Nachrichten
Press Release Distribution & PR Platform - ACCESS Newswire
Does Regulus Therapeutics Inc (NASDAQ:RGLS) Look Expensive At $2.80? Here’s How To Know. - Marketing Sentinel
Should You Buy Regulus (RGLS) After Golden Cross? - Yahoo
Regulus Therapeutics Inc’s latest rating changes from various analysts - knoxdaily.com
Regulus Therapeutics Inc (RGLS) Stock: Navigating a Year of Volatility - investchronicle.com
Plus Therapeutics Inc’s Banking’s 100-Day Moving Average at 1.0899: Will the Stock Break Through? - investchronicle.com
Analytical Overview: Regulus Therapeutics Inc (RGLS)’s Ratios Tell a Financial Story - DWinneX
Taking the lead: Regulus Therapeutics Inc (RGLS) - Sete News
A closer look at Regulus Therapeutics Inc (RGLS)’s stock price trends - uspostnews.com
10 Best Rising Penny Stocks to Buy According to Analysts - Insider Monkey
Is Regulus Therapeutics Inc. (RGLS) the Best Rising Penny Stock to Buy According to Analysts? - Insider Monkey
Regulus Therapeutics (NASDAQ:RGLS) Stock Price Crosses Above 200-Day Moving Average – Time to Sell? - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Stock Price Crosses Above Two Hundred Day Moving Average – Should You Sell? - Defense World
IMPORTANT EQUITY NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit - Longview News-Journal
microRNA Pioneer Regulus Takes Center Stage: CEO to Reveal Latest Developments at Elite Biotech Summit - Stock Titan
Regulus Therapeutics Leads The Charge Among 3 Promising Penny Stocks - simplywall.st
Regulus Therapeutics (NASDAQ:RGLS) Raised to “Overweight” at Wells Fargo & Company - Defense World
Wells Fargo & Company Upgrades Regulus Therapeutics (NASDAQ:RGLS) to “Overweight” - Defense World
Wells Fargo Upgrades Regulus Therapeutics (RGLS) - Nasdaq
Regulus Therapeutics (RGLS) Announces Promising Phase 1b Trial R - GuruFocus.com
Regulus stock jumps after Phase 1 data update (RGLS:NASDAQ) - Seeking Alpha
Wells Fargo Upgrades Regulus Therapeutics to Overweight From Equalweight, $6 Price Target; Share Rise - MarketScreener
Regulus Therapeutics Completes Phase 1b Farabursen Study in Polycystic Kidney Disease - MarketScreener
Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease - Benzinga
Pre-market Movers: RGLS, SLNO, OCEA, OSRH... - RTTNews
Regulus Therapeutics (RGLS) Announces Successful Completion of its Phase 1b MAD Clinical Trial of Farabursen (RGLS8429) for the Treatment of ADPKD - StreetInsider
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose Clinical Trial of Farabursen for the Treatment of Autosomal Dominant Polycystic Kidney Disease - MarketScreener
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Quantisnow
Regulus Announces Positive Phase 1b Study Results - TipRanks
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Dis - StreetInsider.com
Game-Changing Clinical Data: New Drug Stops Kidney Disease Progression in Phase 1b Trial - Stock Titan
Regulus Therapeutics Inc. (NASDAQ:RGLS) Holdings Lowered by Victory Capital Management Inc. - Defense World
Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now - Insider Monkey
Regulus Therapeutics (NASDAQ:RGLS) Receives Buy Rating from Canaccord Genuity Group - Defense World
HC Wainwright Reaffirms “Buy” Rating for Regulus Therapeutics (NASDAQ:RGLS) - Defense World
10 Best Short-Term Stocks to Buy Now with Rebound Potential - Insider Monkey
Is Regulus Therapeutics (NASDAQ:RGLS) In A Good Position To Invest In Growth? - Yahoo
Regulus Therapeutics Reports Positive Trial Results and Financials - TipRanks
H.C. Wainwright maintains Buy on Regulus stock, $10 target - Investing.com
Regulus Therapeutics Q4 Operating Expenses USD 13.746 Million -March 13, 2025 at 05:37 pm EDT - Marketscreener.com
Regulus: Q4 Earnings Snapshot - San Antonio Express-News
Regulus Therapeutics Inc. SEC 10-K Report - TradingView
Regulus: Q4 Earnings Snapshot -March 13, 2025 at 04:19 pm EDT - Marketscreener.com
Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates - PR Newswire
Regulus Therapeutics (RGLS) to Release Quarterly Earnings on Thursday - Defense World
Rhumbline Advisers Lowers Stock Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
AKPKD Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | AceLink Therapeutics, Sanofi, DiNAQOR AG, Poxel, AceLink Therapeutics, Regulus Therapeutics, Reata Pharma - Barchart
AKPKD Pipeline 2024: Key Companies, MOA, ROA, and Clinical - openPR
Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference - PR Newswire
Can Regulus Therapeutics' Conference Appearance Signal New MicroRNA Developments? - Stock Titan
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Regulus Therapeutics’ (RGLS) Buy Rating Reiterated at HC Wainwright - Defense World
RNAi Therapeutics and Technology Market Top Companies Study - openPR.com
Promising Phase 1b Results and FDA Alignment Drive Buy Rating for Regulus Therapeutics - TipRanks
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):